205 related articles for article (PubMed ID: 11404515)
1. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
[TBL] [Abstract][Full Text] [Related]
2. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
3. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
[TBL] [Abstract][Full Text] [Related]
4. Costs of care for HIV infection in a managed care population from 1995 to 1997.
Lapins DL; Urdaneta ME; Barrett J; Hamel EC; Duong PT; Markson LE
Am J Manag Care; 2000 Sep; 6(9):973-81. PubMed ID: 11184068
[TBL] [Abstract][Full Text] [Related]
5. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
6. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital.
Keiser P; Kvanli MB; Turner D; Reisch J; Smith JW; Nassar N; Gregg C; Skiest D
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):28-33. PubMed ID: 9928726
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
8. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
[TBL] [Abstract][Full Text] [Related]
9. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
[TBL] [Abstract][Full Text] [Related]
10. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach.
Le Pen C; Rozenbaum W; Downs A; Maurel F; Lilliu H; Brun C
HIV Clin Trials; 2001; 2(2):136-45. PubMed ID: 11590522
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
13. Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?
Farnham PG
Appl Health Econ Health Policy; 2010; 8(2):75-88. PubMed ID: 20175587
[TBL] [Abstract][Full Text] [Related]
14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
15. Effect of management strategies and clinical status on costs of care for advanced HIV.
Barnett PG; Chow A; Joyce VR; Bayoumi AM; Griffin SC; Sun H; Holodniy M; Brown ST; Cameron W; Sculpher M; Youle M; Anis AH; Owens DK
Am J Manag Care; 2014 May; 20(5):e129-37. PubMed ID: 25326927
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
18. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
19. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
McCabe CJ; Goldie SJ; Fisman DN
PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
